Adult Aged Aged 80 and over Antibodies Monoclonal/therapeutic use Antibodies Monoclonal Humanized/therapeutic use B7-H1 Antigen/*antagonists & inhibitors/genetics CTLA-4 Antigen/*antagonists & inhibitors/genetics Clinical Trials as Topic Female Genes cdc/drug effects Humans Ipilimumab Male Middle Aged Neoplasm Metastasis/*drug therapy/genetics/pathology Nivolumab Urinary Bladder Neoplasms/*drug therapy/genetics/pathology Bladder cancer immunotherapy Checkpoint inhibitor Pembrolizumab

*Health Status Humans *Life Style *Quality of Life Survivors/*psychology Urinary Bladder Neoplasms/*psychology/therapy Bladder cancer Diet Exercise Lifestyle factors Quality of life Smoking Urothelial carcinoma

Adjuvants Immunologic/*therapeutic use BCG Vaccine/*therapeutic use Humans Mycobacterium bovis Urinary Bladder Neoplasms/*drug therapy/pathology BCG vaccine immunotherapy urinary bladder neoplasms

Combined Modality Therapy Cystectomy/*methods Humans Lymph Node Excision/*methods Urinary Bladder Neoplasms/pathology/*surgery

Kaplan-Meier Estimate Neoplasm Grading Neoplasm Metastasis Neoplasm Staging Odds Ratio Prognosis Publication Bias Urinary Bladder Neoplasms/*mortality/*pathology/therapy histological variants squamous differentiation urothelial carcinoma of the bladder including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

Adult Aged Aged 80 and over Female *Fluorodeoxyglucose F18 Humans Lymphatic Metastasis Male Middle Aged Neoplasm Staging *Positron Emission Tomography Computed Tomography *Radiopharmaceuticals Reproducibility of Results Retrospective Studies Urinary Bladder Neoplasms/*drug therapy/*pathology Bladder cancer Lymph nodes Positron emission tomography Preoperative staging Urinary bladder neoplasms

BCG Vaccine/*adverse effects/immunology/therapeutic use C-Reactive Protein/analysis Cancer Vaccines/*adverse effects/immunology/therapeutic use Databases Factual Dysuria/etiology Humans Lymphadenopathy/etiology Pneumonia/etiology Skin Ulcer/etiology Tuberculosis Vaccines/*adverse effects/immunology Urinary Bladder Neoplasms/*therapy

Administration Intravesical Antineoplastic Combined Chemotherapy Protocols/*administration & dosage Carcinoma Transitional Cell/mortality/*pathology/*therapy Disease Progression Doxorubicin/administration & dosage/analogs & derivatives Epirubicin/administration & dosage Humans Mitomycin/administration & dosage Neoplasm Recurrence Local/*prevention & control Neoplasm Staging Randomized Controlled Trials as Topic Risk Factors Survival Rate Thiotepa/administration & dosage Time Factors Urinary Bladder Neoplasms/mortality/*pathology/*therapy Chemotherapy Meta-analysis Non–muscle-invasive bladder cancer Single instillation Systematic review

Administration Intravesical Antineoplastic Agents/administration & dosage/*therapeutic use BCG Vaccine/administration & dosage/*therapeutic use Humans Treatment Outcome Urinary Bladder Neoplasms/*drug therapy

Administration Intravesical Antineoplastic Agents/*administration & dosage Antineoplastic Combined Chemotherapy Protocols/administration & dosage Carcinoma Transitional Cell/*drug therapy/mortality Cyclophosphamide/administration & dosage Doxorubicin/administration & dosage/analogs & derivatives Epirubicin/administration & dosage Humans Melphalan/administration & dosage Network Meta-Analysis Semustine/administration & dosage Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/mortality chemotherapy drug therapy single instillation systematic review urinary bladder neoplasm